Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice

Journal of Lipid Research

Volumn 54, Issue 8, 2013, Pages 2195-2205

  Gautier, Thomas ^a   De Haan, Willeke ^b   Grober, Jacques ^a   Ye, Dan ^c   Bahr, Matthias J ^d   Claudel, Thierry ^a,e   Nijstad, Niels ^a   Van Berkel, Theo J C ^f   Havekes, Louis M ^b   Manns, Michael P ^d   Willems, Stefan M ^g   Hogendoorn, Pancras C W ^g   Lagrost, Laurent ^a   Kuipers, Folkert ^a,d   Van Eck, Miranda ^c   Rensen, Patrick C N ^b   Tietge, Uwe J F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Department of Endocrinology   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bile acids; Hepatocyte; Lipoproteins; Macrophage; Nuclear receptor

Indexed keywords

APOLIPOPROTEIN E; BILE ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BILE ACID BLOOD LEVEL; CELL CULTURE; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION;

EID: 84881256839     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M038141     Document Type: Article

References (47)

1. Masson, D., X. C. Jiang, L. Lagrost, and A. R. Tall.2009.The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J. Lipid Res. 50 (Suppl.) : S201-S206.
2. Barter, P. J., H. B. Brewer, Jr ., M. J. Chapman, C. H. Hennekens, D. J. Rader, and A. R. Tall.2003.Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 : 160-167.
3. Rader, D. J., and A. Daugherty.2008.Translating molecular discoveries into new therapies for atherosclerosis. Nature.451 : 904-913.
4. Boekholdt, S. M., J. A. Kuivenhoven, N. J. Wareham, R. J. Peters, J. W. Jukema, R. Luben, S. A. Bingham, N. E. Day, J. J. Kastelein, and K. T. Khaw.2004.Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: The prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation.110 : 1418-1423.
5. Zeller, M., D. Masson, M. Farnier, L. Lorgis, V. Deckert, J. P. Pais de Barros, C. Desrumaux, P. Sicard, J. Grober, D. Blache, et al.2007. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 50 : 1948-1955.
6. Ridker, P. M., G. Paré, A. N. Parker, R. Y. Zee, J. P. Miletich, and D. I. Chasman.2009.Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18,245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2 : 26-33.
7. Vasan, R. S., M. J. Pencina, S. J. Robins, J. P. Zachariah, G. Kaur, R. B. D'Agostino, and J. M. Ordovas.2009.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation.120 : 2414-2420.
8. Ritsch, A., H. Scharnagl, P. Eller, I. Tancevski, K. Duwensee, E. Demetz, A. Sandhofer, B. O. Boehm, B. R. Winkelmann, J. R. Patsch, et al.2010.Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: The Ludwigshafen Risk and Cardiovascular Health study. Circulation.121 : 366-374.
9. de Vries, R., F. G. Perton, G. M. Dallinga-Thie, A. M. van Roon, B. H. Wolffenbuttel, A. van Tol, and R. P. Dullaart.2005.Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: Role of CETP and triglycerides. Diabetes.54 : 3554-3559.
10. Porez, G., J. Prawitt, B. Gross, and B. Staels.2012.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 53 : 1723-1737.
11. Claudel, T., E. Sturm, H. Duez, I. P. Torra, A. Sirvent, V. Kosykh, J. C. Fruchart, J. Dallongeville, D. W. Hum, F. Kuipers, et al.2002. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109 : 961-971.
12. Sorokin, A., J. L. Brown, and P. D. Thompson.2007.Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis.194 : 293-299.
13. Kuriyama, M., Y. Tokimura, J. Fujiyama, Y. Utatsu, and M. Osame. 1994.Treatment of cerebrotendinous xanthomatosis: Effects of chenodeoxycholic acid, pravastatin, and combined use. J. Neurol. Sci. 125 : 22-28.
14. Leiss, O., and K. von Bergmann.1982.Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand. J. Gastroenterol. 17 : 587-592.
15. Jiang, X. C., L. B. Agellon, A. Walsh, J. L. Breslow, and A. Tall. 1992.Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural fl anking sequences. J. Clin. Invest. 90 : 1290-1295.
16. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006.Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26 : 2552-2559.
17. Quintao, E. C. R., and P. M. Cazita.2010.Lipid transfer proteins: Past, present and perspectives. Atherosclerosis.209 : 1-9.
18. Gautier, T., U. J. F. Tietge, R. Boverhof, F. G. Perton, N. Le Guern, D. Masson, P. C. Rensen, L. M. Havekes, L. Lagrost, and F. Kuipers. 2007.Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein. J. Lipid Res. 48 : 30-40.
19. Guyard-Dangremont, V., L. Lagrost, P. Gambert, and C. Lallemant. 1994.Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP). Clin. Chim. Acta. 231 : 147-160.
20. Wiersma, H., A. Gatti, N. Nijstad, R. P. Oude Elferink, F. Kuipers, and U. J. F. Tietge.2009.Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter G5/G8 in mice. Hepatology.50 : 1263-1272.
21. Wiersma, H., N. Nijstad, J. F. de Boer, R. Out, W. Hogewerf, T. J. Van Berkel, F. Kuipers, and U. J. Tietge.2009.Lack of ABCG1 results in decreased plasma HDL cholesterol levels and increased biliary cholesterol secretion in mice fed a high cholesterol diet. Atherosclerosis.206 : 141-147.
22. Hulzebos, C. V., L. Renfurm, R. H. Bandsma, H. J. Verkade, T. Boer, R. Boverhof, H. Tanaka, I. Mierau, P. J. Sauer, F. Kuipers, et al.2001.Measurement of parameters of cholic acid kinetics in plasma using a microscale stable isotope dilution technique: Application to rodents and humans. J. Lipid Res. 42 : 1923-1929.
23. Glasova, H., T. M. Berghaus, G. A. Kullak-Ublick, G. Paumgartner, and U. Beuers.2002.Tauroursodeoxycholic acid mobilizes alpha-PKC after uptake in human HepG2 hepatoma cells. Eur. J. Clin. Invest. 32 : 437-442.
24. Drayna, D., A. S. Jarnagin, J. McLean, W. Henzel, W. Kohr, C. Fielding, and R. Lawn.1987.Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature.327 : 632-634.
25. Sandelin, A., and W. W. Wasserman.2005.Prediction of nuclear hormone receptor response elements. Mol. Endocrinol. 19 : 595-606.
26. Claudel, T., Y. Inoue, O. Barbier, D. Duran-Sandoval, V. Kosykh, J. Fruchart, J. C. Fruchart, F. J. Gonzalez, and B. Staels.2003. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology.125 : 544-555.
27. Gardès, C., D. Blum, K. Bleicher, E. Chaput, M. Ebeling, P. Hartman, C. Handschin, H. Richter, and G. M. Benson.2011. Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor. J. Lipid Res. 52 : 1188-1199.
28. Van Eck, M., D. Ye, R. B. Hildebrand, J. K. Kruijt, W. de Haan, M. Hoekstra, P. C. Rensen, C. Ehnholm, M. Jauhiainen, and T. J. Van Berkel.2007.Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ. Res. 100 : 678-685.
29. Luo, Y., and A. R. Tall.2000.Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105 : 513-520.
30. Edwards, P. A., H. R. Kast, and A. M. Anisfeld.2002.BAREing it all: The adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43 : 2-12.
31. Grober, J., I. Zaghini, H. Fujii, S. A. Jones, S. A. Kliewer, T. M. Willson, T. Ono, and P. Besnard.1999.Identification of a bile acidresponsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274 : 29749-29754.
32. Srivastava, R. A., N. Srivastava, and M. Averna.2000.Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. Eur. J. Biochem. 267 : 4272-4280.
33. Lefebvre, P., B. Cariou, F. Lien, F. Kuipers, and B. Staels.2009. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89 : 147-191.
34. Iglesias, A., M. Arranz, J. J. Alvarez, J. Perales, J. Villar, E. Herrera, and M. A. Lasunción.1996.Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. Clin. Chim. Acta.248 : 157-174.
35. Nagasaka, H., T. Miida, K. Hirano, A. Ota, K. Murayama, T. Yorifuji, K. Kobayashi, T. Takatani, H. Tsukahara, S. P. Hui, et al.2008. Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome. Atherosclerosis.198 : 434-440.
36. Kinoshita, M., M. Kawamura, M. Fujita, D. Hirota, T. Suda, M. Taki, J. Kusano, K. Takao, H. Takenaka, S. Kubota, et al.2004.Enhanced susceptibility of LDL to oxidative modification in a CTX patient: Role of chenodeoxycholic acid in xanthoma formation. J. Atheroscler. Thromb. 11 : 167-172.
37. Gauthier, B., M. Robb, F. Gaudet, G. S. Ginsburg, and R. McPherson. 1999.Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: Functional role of the transcription factors SREBP-1a,-2, and YY1. J. Lipid Res. 40 : 1284-1293.
38. Chouinard, R. A., Jr ., Y. Luo, T. F. Osborne, A. Walsh, and A. R. Tall.1998.Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vivo but is not required for sterol up-regulation of gene expression. J. Biol. Chem. 273 : 22409-22414.
39. Luo, Y., C. P. Liang, and A. R. Tall.2001.The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J. Biol. Chem. 276 : 24767-24773.
40. Masucci-Magoulas, L., P. Moulin, X. C. Jiang, H. Richardson, A. Walsh, J. L. Breslow, and A. Tall.1995.Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J. Clin. Invest. 95 : 1587-1594.
41. Lakomy, D., C. Rébé, A. L. Sberna, D. Masson, T. Gautier, A. Chevriaux, M. Raveneau, N. Ogier, A. T. Nguyen, P. Gambert, et al. 2009.Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. Arterioscler. Thromb. Vasc. Biol. 29 : 1923-1929.
42. Zhang, Y., X. Wang, C. Vales, F. Y. Lee, H. Lee, A. J. Lusis, and P. A. Edwards.2006.FXR deficiency causes reduced atherosclerosis in Ldlr-/-mice. Arterioscler. Thromb. Vasc. Biol. 26 : 2316-2321.
43. Hanniman, E. A., G. Lambert, T. C. McCarthy, and C. J. Sinal. 2005.Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46 : 2595-2604.
44. Hartman, H. B., S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans.2009.Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/-and apoE-/-mice. J. Lipid Res. 50 : 1090-1100.
45. Hambruch, E., S. Miyazaki-Anzai, U. Hahn, S. Matysik, A. Boettcher, S. Perović-Ottstadt, T. Schlüter, O. Kinzel, H. D. Krol, U. Deuschle, et al.2012.Synthetic farnesoid X receptor agonists induce highdensity lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J. Pharmacol. Exp. Ther. 343 : 556-567.
46. Gardes, C., E. Chaput, A. Staempfli, D. Blum, H. Richter, and G. M. Benson.2013.Differential regulation of bile acid and cholesterol metabolism by the farnesoid-X-receptor in Ldlr-/-mice versus hamsters. J. Lipid Res. 54: 1283-1299.
47. Forman, B. M., E. Goode, J. Chen, A. E. Oro, D. J. Bradley, T. Perlmann, D. J. Noonan, L. T. Burka, T. McMorris, W. W. Lamph, et al.1995.Identification of a nuclear receptor that is activated by farnesol metabolites. Cell.81 : 687-693.